S921

Tyler's Law, S.921, mandates the Secretary of Health and Human Services (HHS) to complete a study within one year of enactment. This study will assess the frequency, costs, benefits, risks, and patient impact of fentanyl testing in hospital emergency departments. Following the study, HHS must issue guidance within six months on whether routine fentanyl testing should be implemented, how hospitals can ensure clinicians are aware of drug tests, and the impact of testing on future overdose risk and health outcomes. This bill does not directly mandate fentanyl testing but establishes a framework for potential future mandates or recommendations. The money trail for this bill is indirect. There are no direct appropriations for the study or guidance. However, if HHS guidance recommends routine fentanyl testing, it will create a new demand for fentanyl test kits and laboratory services. Companies that manufacture diagnostic tests and provide laboratory services stand to gain. The study itself will likely involve data collection from existing healthcare providers and may involve contracting with research organizations. Historically, legislative actions that lead to new diagnostic testing requirements have created market opportunities. For example, the Protecting Access to Medicare Act (PAMA) of 2014, which reformed clinical laboratory payment systems, led to increased scrutiny and consolidation in the lab testing sector. While not directly comparable, any federal guidance recommending specific testing procedures drives demand for the associated diagnostics. The market for drug testing, including fentanyl, has seen consistent growth due to the opioid crisis. Specific historical precedents for federal guidance on emergency department testing leading to significant market shifts are limited, as most testing decisions are made at the hospital or state level. Specific companies that stand to gain if routine fentanyl testing is recommended include major diagnostic test manufacturers and laboratory service providers. Companies like LabCorp ($LH) and Quest Diagnostics ($DGX), which offer extensive drug testing panels, would see increased volume. Diagnostic equipment and reagent manufacturers such as Thermo Fisher Scientific ($TMO) and PerkinElmer, which produce fentanyl testing kits and mass spectrometry equipment, would also benefit from increased demand. There are no clear losers from this bill, as it primarily focuses on study and guidance. The timeline is clear: a study within one year of enactment, followed by guidance within six months of the study's completion. This means any market impact from potential widespread adoption of fentanyl testing is at least 18 months away, assuming the bill passes and is enacted. The bill is currently on the Senate Legislative Calendar, indicating it has cleared committee and is awaiting a vote.